Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine, Capecitabine, and Bevacizumab in Metastatic Renal Cell Carcinoma
NCT00523640Phase 2Terminated
- Sponsor
- University of Chicago
- Start
- Mar 2005
- Primary completion
- Apr 2011
- Modality
- Monoclonal Antibodies, DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of gemcitabine, capecitabine, bevacizumab in renal cell carcinoma (RCC), sponsored by University of Chicago. Started Mar 2005; status: terminated.
02
Drugs
gemcitabinecapecitabinebevacizumab
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT00523640.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00523640.